Reviewer's report 
 Efficacy of Rifabutin-based Triple Teraphy as Second-line to Eradicate Helicobacter Pylori Infection Title: 
 1  10 February 2007 Version: Date: 
 Giovanni Cammarota Reviewer: 
Reviewer's report: 
General: The present study is the first clinical trial designed to compare, as a second-line treatment, a 
rifabutin-based regimen with standard quadruple therapy. The study is well designed and conducted. The 
relevant literature is sufficiently reflected in the paper.Although the study provides negative results, I think it should be published. Rifabutin is used as a salvage treatment against mycobacterium tuberculosis and as prophylactic against the mycobacterium avium infection in HIV-positive patients. It should be used, 
therefore, with prudence in order to avoid an increasing of resistance to this drug. 
------------------------------------------------------------------------------- 
Major Compulsory Revisions (that the author must respond to before a decision on publication can be 
reached): None. 
------------------------------------------------------------------------------- 
Minor Essential Revisions (such as missing labels on figures, or the wrong use of a term, which the author 
can be trusted to correct): 
In the Discussion session, it should be mentioned that different geographical areas may reflect the different 
results obtained by other study. For example, another study conducted in Spain (Gisbert JP et al Aliment 
Pharmacol Ther 2006;24(10):1469-74) achieved similar negative findings by using a third-line savage 
package containing a rifabutin-based triple regimen (the study should be cited). 
The English should be revised. 
------------------------------------------------------------------------------- 
Discretionary Revisions (which the author can choose to ignore) 
 Accept after minor essential revisions What next?: 
 An article whose findings are important to those with closely related research interests Level of interest: 
 Needs some language corrections before being published Quality of written English: 
 No, the manuscript does not need to be seen by a statistician. Statistical review: 
Declaration of competing interests: 
I declare that I have no competing interests. 
Reviewer's report 
 Efficacy of Rifabutin-based Triple Teraphy as Second-line to Eradicate Helicobacter Pylori Infection Title: 
 1  10 February 2007 Version: Date: 
 Giovanni Cammarota Reviewer: 
Reviewer's report: 
General: The present study is the first clinical trial designed to compare, as a second-line treatment, a 
rifabutin-based regimen with standard quadruple therapy. The study is well designed and conducted. The 
relevant literature is sufficiently reflected in the paper.Although the study provides negative results, I think it should be published. Rifabutin is used as a salvage treatment against mycobacterium tuberculosis and as prophylactic against the mycobacterium avium infection in HIV-positive patients. It should be used, 
therefore, with prudence in order to avoid an increasing of resistance to this drug. 
------------------------------------------------------------------------------- 
Major Compulsory Revisions (that the author must respond to before a decision on publication can be 
reached): None. 
------------------------------------------------------------------------------- 
Minor Essential Revisions (such as missing labels on figures, or the wrong use of a term, which the author 
can be trusted to correct): 
In the Discussion session, it should be mentioned that different geographical areas may reflect the different 
results obtained by other study. For example, another study conducted in Spain (Gisbert JP et al Aliment 
Pharmacol Ther 2006;24(10):1469-74) achieved similar negative findings by using a third-line savage 
package containing a rifabutin-based triple regimen (the study should be cited). 
The English should be revised. 
------------------------------------------------------------------------------- 
Discretionary Revisions (which the author can choose to ignore) 
 Accept after minor essential revisions What next?: 
 An article whose findings are important to those with closely related research interests Level of interest: 
 Needs some language corrections before being published Quality of written English: 
 No, the manuscript does not need to be seen by a statistician. Statistical review: 
Declaration of competing interests: 
I declare that I have no competing interests. 
Please review this paper.
user
Reviewer's report 
 Efficacy of Rifabutin-based Triple Teraphy as Second-line to Eradicate Helicobacter Pylori Infection Title: 
 1  10 February 2007 Version: Date: 
 Giovanni Cammarota Reviewer: 
Reviewer's report: 
General: The present study is the first clinical trial designed to compare, as a second-line treatment, a 
rifabutin-based regimen with standard quadruple therapy. The study is well designed and conducted. The 
relevant literature is sufficiently reflected in the paper.Although the study provides negative results, I think it should be published. Rifabutin is used as a salvage treatment against mycobacterium tuberculosis and as prophylactic against the mycobacterium avium infection in HIV-positive patients. It should be used, 
therefore, with prudence in order to avoid an increasing of resistance to this drug. 
------------------------------------------------------------------------------- 
Major Compulsory Revisions (that the author must respond to before a decision on publication can be 
reached): None. 
------------------------------------------------------------------------------- 
Minor Essential Revisions (such as missing labels on figures, or the wrong use of a term, which the author 
can be trusted to correct): 
In the Discussion session, it should be mentioned that different geographical areas may reflect the different 
results obtained by other study. For example, another study conducted in Spain (Gisbert JP et al Aliment 
Pharmacol Ther 2006;24(10):1469-74) achieved similar negative findings by using a third-line savage 
package containing a rifabutin-based triple regimen (the study should be cited). 
The English should be revised. 
------------------------------------------------------------------------------- 
Discretionary Revisions (which the author can choose to ignore) 
 Accept after minor essential revisions What next?: 
 An article whose findings are important to those with closely related research interests Level of interest: 
 Needs some language corrections before being published Quality of written English: 
 No, the manuscript does not need to be seen by a statistician. Statistical review: 
Declaration of competing interests: 
I declare that I have no competing interests. 
assistant